Shanghai Runda Medical Technology Past Earnings Performance
Past criteria checks 4/6
Shanghai Runda Medical Technology has been growing earnings at an average annual rate of 9.7%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 12.4% per year. Shanghai Runda Medical Technology's return on equity is 10.7%, and it has net margins of 4.1%.
Key information
9.7%
Earnings growth rate
9.9%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 12.4% |
Return on equity | 10.7% |
Net Margin | 4.1% |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Does Shanghai Runda Medical Technology (SHSE:603108) Deserve A Spot On Your Watchlist?
Mar 21Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) Stock Rockets 31% But Many Are Still Ignoring The Company
Mar 04These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively
Feb 27Revenue & Expenses BreakdownBeta
How Shanghai Runda Medical Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 9,751 | 395 | 1,728 | 149 |
30 Jun 23 | 10,255 | 433 | 1,790 | 153 |
31 Mar 23 | 10,504 | 457 | 1,764 | 147 |
31 Dec 22 | 10,494 | 418 | 1,776 | 146 |
30 Sep 22 | 9,854 | 365 | 1,512 | 141 |
30 Jun 22 | 9,378 | 336 | 1,402 | 130 |
31 Mar 22 | 9,008 | 332 | 1,371 | 127 |
31 Dec 21 | 8,860 | 380 | 1,295 | 123 |
30 Sep 21 | 8,784 | 416 | 1,325 | 113 |
30 Jun 21 | 8,369 | 422 | 1,264 | 105 |
31 Mar 21 | 7,790 | 388 | 1,166 | 99 |
31 Dec 20 | 7,069 | 330 | 1,066 | 87 |
30 Sep 20 | 6,784 | 253 | 1,016 | 78 |
30 Jun 20 | 6,700 | 246 | 989 | 69 |
31 Mar 20 | 6,820 | 273 | 989 | 65 |
31 Dec 19 | 7,052 | 310 | 995 | 59 |
30 Sep 19 | 6,821 | 311 | 947 | 55 |
30 Jun 19 | 6,464 | 292 | 872 | 54 |
31 Mar 19 | 6,200 | 273 | 868 | 46 |
31 Dec 18 | 5,964 | 262 | 835 | 44 |
30 Sep 18 | 5,729 | 295 | 795 | 34 |
30 Jun 18 | 5,351 | 267 | 757 | 47 |
31 Mar 18 | 4,855 | 242 | 709 | 41 |
31 Dec 17 | 4,319 | 219 | 677 | 33 |
30 Sep 17 | 3,642 | 199 | 570 | 27 |
30 Jun 17 | 3,029 | 164 | 540 | 0 |
31 Mar 17 | 2,516 | 134 | 453 | 0 |
31 Dec 16 | 2,165 | 116 | 391 | 0 |
30 Sep 16 | 1,948 | 115 | 315 | 0 |
30 Jun 16 | 1,812 | 105 | 301 | 0 |
31 Mar 16 | 1,721 | 95 | 279 | 0 |
31 Dec 15 | 1,629 | 92 | 268 | 0 |
30 Sep 15 | 1,528 | 92 | 239 | 0 |
30 Jun 15 | 1,483 | 84 | 226 | 0 |
31 Mar 15 | 1,420 | 81 | 216 | 0 |
31 Dec 14 | 1,359 | 75 | 205 | 0 |
31 Dec 13 | 1,026 | 68 | 157 | 0 |
Quality Earnings: 603108 has high quality earnings.
Growing Profit Margin: 603108's current net profit margins (4.1%) are higher than last year (3.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603108's earnings have grown by 9.7% per year over the past 5 years.
Accelerating Growth: 603108's earnings growth over the past year (8.4%) is below its 5-year average (9.7% per year).
Earnings vs Industry: 603108 earnings growth over the past year (8.4%) exceeded the Life Sciences industry 1.1%.
Return on Equity
High ROE: 603108's Return on Equity (10.7%) is considered low.